STOCK TITAN

[Form 4] Twist Bioscience Corporation Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 overview: On 06/16/2025, Twist Bioscience Corporation (TWST) officer Dennis Cho executed a mandatory “sell-to-cover” transaction, disposing of 94 common shares at $33.475 per share to satisfy tax-withholding obligations arising from vested Restricted Stock Units. This was not a discretionary trade under Rule 10b5-1.

After the sale, Cho continues to beneficially own 104,967 TWST shares and remains Senior Vice President, Chief Legal Officer & Corporate Secretary. The divestiture represents well under 0.1 % of his holdings, leaving insider ownership essentially unchanged and providing limited informational value for investors.

Panoramica del Modulo 4: Il 16/06/2025, l'ufficiale di Twist Bioscience Corporation (TWST), Dennis Cho, ha effettuato una transazione obbligatoria di "vendita per copertura", cedendo 94 azioni ordinarie a 33,475 $ ciascuna per adempiere agli obblighi fiscali derivanti da Restricted Stock Units maturate. Questa operazione non è stata una transazione discrezionale ai sensi della Regola 10b5-1.

Dopo la vendita, Cho continua a detenere beneficiariamente 104.967 azioni TWST e mantiene la carica di Senior Vice President, Chief Legal Officer & Corporate Secretary. La cessione rappresenta meno dello 0,1% delle sue partecipazioni, lasciando sostanzialmente invariata la proprietà interna e fornendo un valore informativo limitato per gli investitori.

Resumen del Formulario 4: El 16/06/2025, el ejecutivo de Twist Bioscience Corporation (TWST), Dennis Cho, realizó una transacción obligatoria de "venta para cubrir", disponiendo de 94 acciones comunes a 33,475 $ por acción para cumplir con las obligaciones fiscales derivadas de Unidades de Acciones Restringidas adquiridas. Esta no fue una operación discrecional bajo la Regla 10b5-1.

Después de la venta, Cho continúa siendo beneficiario de 104,967 acciones de TWST y sigue siendo Vicepresidente Senior, Director Legal y Secretario Corporativo. La desinversión representa menos del 0,1 % de sus participaciones, dejando la propiedad interna prácticamente sin cambios y aportando un valor informativo limitado para los inversores.

Form 4 개요: 2025년 6월 16일, Twist Bioscience Corporation(TWST)의 임원 Dennis Cho는 의무적인 '매도-커버' 거래를 실행하여, 취득된 제한 주식 단위(RSU)에 따른 세금 원천징수 의무를 충족하기 위해 주당 33.475달러에 보통주 94주를 처분했습니다. 이 거래는 Rule 10b5-1에 따른 임의 거래가 아니었습니다.

매도 후 Cho는 여전히 104,967주의 TWST 주식을 실질적으로 보유하고 있으며, 수석 부사장, 최고 법률 책임자 및 회사 비서직을 유지하고 있습니다. 이번 처분은 그의 보유 지분의 0.1% 미만에 해당하여 내부자 지분에 거의 변동이 없으며 투자자에게 제공하는 정보 가치도 제한적입니다.

Vue d'ensemble du Formulaire 4 : Le 16/06/2025, Dennis Cho, cadre de Twist Bioscience Corporation (TWST), a réalisé une transaction obligatoire de "vente pour couvrir", cédant 94 actions ordinaires au prix de 33,475 $ par action afin de satisfaire aux obligations fiscales liées à des unités d'actions restreintes acquises. Il ne s'agissait pas d'une opération discrétionnaire selon la règle 10b5-1.

Après la vente, Cho détient toujours bénéficiairement 104 967 actions TWST et reste Senior Vice President, Chief Legal Officer & Corporate Secretary. Cette cession représente bien moins de 0,1 % de ses avoirs, laissant la participation des initiés pratiquement inchangée et offrant une valeur informative limitée aux investisseurs.

Überblick über Formular 4: Am 16.06.2025 führte Dennis Cho, ein leitender Angestellter der Twist Bioscience Corporation (TWST), eine verpflichtende "Sell-to-Cover"-Transaktion durch, bei der er 94 Stammaktien zu je 33,475 $ verkaufte, um Steuerabzugsverpflichtungen aus ausgeübten Restricted Stock Units zu erfüllen. Dies war kein diskretionärer Handel gemäß Regel 10b5-1.

Nach dem Verkauf hält Cho weiterhin wirtschaftlich 104.967 TWST-Aktien und bekleidet die Position des Senior Vice President, Chief Legal Officer & Corporate Secretary. Die Veräußerung macht weniger als 0,1 % seines Bestands aus, wodurch die Insider-Beteiligung praktisch unverändert bleibt und für Investoren nur begrenzte Informationswerte bietet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Very small, tax-related insider sale; ownership and sentiment unchanged—overall neutral.

The filing shows a routine 94-share sale (about 0.09 % of the insider’s position) priced at $33.475. Because the trade was required to cover RSU tax withholding and not an elective disposal, it does not signal a change in the insider’s confidence or the company’s prospects. Post-transaction ownership of 104,967 shares remains substantial, so the governance impact and potential market reaction should be negligible.

Panoramica del Modulo 4: Il 16/06/2025, l'ufficiale di Twist Bioscience Corporation (TWST), Dennis Cho, ha effettuato una transazione obbligatoria di "vendita per copertura", cedendo 94 azioni ordinarie a 33,475 $ ciascuna per adempiere agli obblighi fiscali derivanti da Restricted Stock Units maturate. Questa operazione non è stata una transazione discrezionale ai sensi della Regola 10b5-1.

Dopo la vendita, Cho continua a detenere beneficiariamente 104.967 azioni TWST e mantiene la carica di Senior Vice President, Chief Legal Officer & Corporate Secretary. La cessione rappresenta meno dello 0,1% delle sue partecipazioni, lasciando sostanzialmente invariata la proprietà interna e fornendo un valore informativo limitato per gli investitori.

Resumen del Formulario 4: El 16/06/2025, el ejecutivo de Twist Bioscience Corporation (TWST), Dennis Cho, realizó una transacción obligatoria de "venta para cubrir", disponiendo de 94 acciones comunes a 33,475 $ por acción para cumplir con las obligaciones fiscales derivadas de Unidades de Acciones Restringidas adquiridas. Esta no fue una operación discrecional bajo la Regla 10b5-1.

Después de la venta, Cho continúa siendo beneficiario de 104,967 acciones de TWST y sigue siendo Vicepresidente Senior, Director Legal y Secretario Corporativo. La desinversión representa menos del 0,1 % de sus participaciones, dejando la propiedad interna prácticamente sin cambios y aportando un valor informativo limitado para los inversores.

Form 4 개요: 2025년 6월 16일, Twist Bioscience Corporation(TWST)의 임원 Dennis Cho는 의무적인 '매도-커버' 거래를 실행하여, 취득된 제한 주식 단위(RSU)에 따른 세금 원천징수 의무를 충족하기 위해 주당 33.475달러에 보통주 94주를 처분했습니다. 이 거래는 Rule 10b5-1에 따른 임의 거래가 아니었습니다.

매도 후 Cho는 여전히 104,967주의 TWST 주식을 실질적으로 보유하고 있으며, 수석 부사장, 최고 법률 책임자 및 회사 비서직을 유지하고 있습니다. 이번 처분은 그의 보유 지분의 0.1% 미만에 해당하여 내부자 지분에 거의 변동이 없으며 투자자에게 제공하는 정보 가치도 제한적입니다.

Vue d'ensemble du Formulaire 4 : Le 16/06/2025, Dennis Cho, cadre de Twist Bioscience Corporation (TWST), a réalisé une transaction obligatoire de "vente pour couvrir", cédant 94 actions ordinaires au prix de 33,475 $ par action afin de satisfaire aux obligations fiscales liées à des unités d'actions restreintes acquises. Il ne s'agissait pas d'une opération discrétionnaire selon la règle 10b5-1.

Après la vente, Cho détient toujours bénéficiairement 104 967 actions TWST et reste Senior Vice President, Chief Legal Officer & Corporate Secretary. Cette cession représente bien moins de 0,1 % de ses avoirs, laissant la participation des initiés pratiquement inchangée et offrant une valeur informative limitée aux investisseurs.

Überblick über Formular 4: Am 16.06.2025 führte Dennis Cho, ein leitender Angestellter der Twist Bioscience Corporation (TWST), eine verpflichtende "Sell-to-Cover"-Transaktion durch, bei der er 94 Stammaktien zu je 33,475 $ verkaufte, um Steuerabzugsverpflichtungen aus ausgeübten Restricted Stock Units zu erfüllen. Dies war kein diskretionärer Handel gemäß Regel 10b5-1.

Nach dem Verkauf hält Cho weiterhin wirtschaftlich 104.967 TWST-Aktien und bekleidet die Position des Senior Vice President, Chief Legal Officer & Corporate Secretary. Die Veräußerung macht weniger als 0,1 % seines Bestands aus, wodurch die Insider-Beteiligung praktisch unverändert bleibt und für Investoren nur begrenzte Informationswerte bietet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cho Dennis

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S 94(1) D $33.475 104,967 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Remarks:
Senior Vice President, Chief Legal Officer & Corporate Secretary
/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Twist Bioscience7s (TWST) Form 4 filed on 06/18/2025 disclose?

An officer sold 94 common shares on 06/16/2025 at $33.475 to cover RSU tax withholding.

How many TWST shares did insider Dennis Cho sell?

94 shares of common stock.

Why were the TWST shares sold by Dennis Cho?

The sale was a mandatory “sell-to-cover” to pay taxes on vested Restricted Stock Units.

How many TWST shares does Dennis Cho own after the transaction?

104,967 shares.

At what price were the TWST shares sold?

$33.475 per share.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.08B
58.73M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO